Dr. James Treanor is an experienced Chief Officer and a strong business development professional skilled in Small Molecules, Drug Development, Assay Development, Antibodies, and Translational Medicine. He currently serves as a member of the Board of Directors and the Scientific Advisory Board (SAB) at ADRx, Inc, where he is the former CEO. He is also currently serves on the SAB member at Switch Therapeutics and Karma Biotechnologies. In his prior role as CSO at Neuron23 and Executive Scientific director at Amgen, Inc. he advanced clinical assets for Parkinson’s disease, Alzheimer’s disease, schizophrenia, chronic pain, and Migraine. James earned his Ph.D. in molecular neurobiology from the University of Bristol and conducted his postdoctoral training at Genentech under the guidance of Franz Hefti, Arnon Rosenthal & Gene Burton.

• Current BOD, SAB member, and former CEO at ADRx, Inc. 
• SAB member at Switch Therapeutics;  Karma Biotechnologies.
• Former CSO at Neuron23; Executive Scientific Director at Amgen, Inc.
• Advanced clinical assets for Parkinson’s disease, Alzheimer’s disease, schizophrenia, chronic pain, and Migraine.